In 2021, an Indian team published a detailed case report of a 36-year-old woman who developed Stevens-Johnson syndrome, a serious disorder affecting the skin and mucous membranes, which was attributed to oral terbinafine used to treat a fungal toenail infection (onycho-mycosis). The condition began one week after terbinafine was initiated at a dose of 250 mg per day, which is the dose usually recommended. The patient initially developed a fever, with mucosal lesions (erythema, haem-orrhagic crusting, and painful lesions affecting the lips, mouth, eye and genitals), leading to difficulty eating and drinking, photophobia and painful micturition.
展开▼
